J2860 Injection, siltuximab
Also known as: siltuximab, sylvant
Injection of siltuximab (Sylvant), a monoclonal antibody against interleukin-6 (IL-6) used for treatment of multicentric Castleman disease (MCD).
In Plain Language
rare disease treatment; lymph node disease medication
Clinical Context
Used for multicentric Castleman disease (MCD) in human immunodeficiency virus (HIV)-negative and hepatitis C virus (HCV)-negative patients.
RVU Information
CPT J2860 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.
Billing & Documentation
J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.
Specialties
Frequently Asked Questions
What is CPT code J2860?
CPT J2860 (Injection, siltuximab) is a J Codes (Drugs) code. Injection of siltuximab (Sylvant), a monoclonal antibody against interleukin-6 (IL-6) used for treatment of multicentric Castleman disease (MCD).
How is J2860 administered?
CPT J2860 is administered by a healthcare provider, typically via injection or infusion. Used for multicentric Castleman disease (MCD) in human immunodeficiency virus (HIV)-negative and hepatitis C virus (HCV)-negative patients. It is used by Hematology, Oncology.
When is CPT J2860 used?
Used for multicentric Castleman disease (MCD) in human immunodeficiency virus (HIV)-negative and hepatitis C virus (HCV)-negative patients.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.